The proximal origin of SARS-CoV-2.
Nat Med. 2020; 26: 450-452
COVID-19 coronavirus pandemic.
COVID-19 dashboard by the Center for Systems Science and Engineering (CSS) at Johns Hopkins University (JHU).
Persistent symptoms in patients after acute COVID-19.
JAMA. 2020; 324: 603-605
Neurologic features in severe SARS-CoV-2 infection.
N Engl J Med. 2020; 382: 2268-2270
Long term respiratory complications of covid-19.
BMJ. 2020; 370m3001
Learning from a retraction.
Lancet. 2020; 3961056
Misinformation during the coronavirus disease 2019 outbreak: how knowledge emerges from noise.
Crit Care Explor. 2020; 2e0098
The Conversation: Coronavirus research done too fast is testing publishing safeguards, bad science is getting through.
Scientists cut peer-review corners under pressure of COVID-19 pandemic.
SARS-CoV-2/COVID-19: evolving reality, global response, knowledge gaps, and opportunities.
Shock. 2020; 54: 416-437
Frequently asked questions about SARS.
Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia.
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2.
Science. 2020; 369: 1249-1255
Evasion of type I interferon by SARS-CoV-2.
Cell Rep. 2020; 33108234
Mechanisms of SARS-CoV-2 transmission and pathogenesis.
Trends Immunol. 2020; 41: 1100-1115
Detection of SARS-CoV-2 in different types of clinical specimens.
JAMA. 2020; 323: 1843-1844
Evidence for gastrointestinal infection of SARS-CoV-2.
Gastroenterology. 2020; 158: 1831-1833.e3
Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells.
Cell Rep. 2020; 32107863
Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response.
Virology. 2014; 454–455: 197-205
Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis.
J Virol. 2005; 79: 7819-7826
Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis.
J Infect Dis. 2014; 209: 1331-1342
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes.
medRxiv. 2020; ()
Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients.
EBioMedicine. 2020; 57102833
Virological assessment of hospitalized patients with COVID-2019.
Nature. 2020; 581: 465-469
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.
Science. 2020; 368: 1012-1015
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
Lancet. 2003; 361: 1767-1772
Viral load of SARS-CoV-2 in clinical samples.
Lancet Infect Dis. 2020; 20: 411-412
Temporal dynamics in viral shedding and transmissibility of COVID-19.
Nat Med. 2020; 26: 672-675
Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection.
Clin Infect Dis. 2016; 62: 477-483
Upper respiratory tract levels of SARS-CoV-2 RNA and duration of viral RNA shedding do not differ between patients with mild and severe/critical COVID-19.
J Infect Dis. 2021; 223: 15-18
SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
Science. 2020; 369: 812-817
Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.
Immunity. 2020; 52: 971-977.e3
Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak—the CoNAN study.
Clin Microbiol Infect. 2021; 27: 470.e1-470.e9
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19.
Cell. 2020; 183: 158-168.e14
Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19.
N Engl J Med. 2020; 383: 1085-1087
Disappearance of antibodies to SARS-associated coronavirus after recovery.
N Engl J Med. 2007; 357: 1162-1163
Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study.
J Immunol. 2011; 186: 7264-7268
Duration of antibody responses after severe acute respiratory syndrome.
Emerg Infect Dis. 2007; 13: 1562-1564
Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers.
medRxiv. 2020; ()
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Science. 2021; 371eabf4063
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
Nature. 2020; 584: 457-462
SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection.
Sci Immunol. 2020; 5eabd6160
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.
Science. 2020; 370: 89-94
Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC.
J Infect. 2013; 67: 348-350
Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43.
J Infect Dis. 2005; 191: 2033-2037
Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63.
Clin Diagn Lab Immunol. 2005; 12: 1317-1321
Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.
Cell Rep. 2020; 31107725
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
Sci Immunol. 2020; 5eabc8413
vWei P-F, ed. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J (Engl) 2020; 133: 1087–95.
The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41: 145-151
SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract.
Cell. 2020; 182: 429-446.e14
Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1.
Chest. 2020; 158: 195-205
Genomewide association study of severe Covid-19 with respiratory failure.
N Engl J Med. 2020; 383: 1522-1534
Possible silent hypoxemia in a COVID-19 patient: a case report.
Ann Med Surg (Lond). 2020; 60: 583-586
The pathophysiology of ‘happy’ hypoxemia in COVID-19.
Respir Res. 2020; 21: 198
Clinical characteristics of coronavirus disease 2019 in China.
N Engl J Med. 2020; 382: 1708-1720
Pathophysiology of dyspnea.
N Engl J Med. 1995; 333: 1547-1553
Measuring the ventilatory response to hypoxia.
J Physiol. 2007; 584: 285-293
Mechanical ventilation to minimize progression of lung injury in acute respiratory failure.
Am J Respir Crit Care Med. 2017; 195: 438-442
Why COVID-19 silent hypoxemia is baffling to physicians.
Am J Respir Crit Care Med. 2020; 202: 356-360
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.
Eur Respir J. 2020; 552001217
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT.
Lancet Infect Dis. 2020; 20: 1365-1366
SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19.
Cancer Cell. 2020; 38: 661-671.e2
Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019.
Clin Infect Dis. 2020; ()
The protein expression profile of ACE2 in human tissues.
Mol Syst Biol. 2020; 16e9610
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
Cell. 2020; 181: 271-280.e8
The microbiome and the respiratory tract.
Annu Rev Physiol. 2016; 78: 481-504
Airborne transmission of SARS-CoV-2: the world should face the reality.
Environ Int. 2020; 139105730
Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review.
Anaesthesia. 2020; 75: 1086-1095
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
Science. 2020; 370: 856-860
AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells.
Cell Res. 2021; 31: 126-140
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.
Lancet Infect Dis. 2020; 20: 1135-1140
Presence of hyaluronan in lung alveoli in severe Covid-19: an opening for new treatment options?.
J Biol Chem. 2020; 295: 15418-15422
Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient.
Cell Res. 2020; 30: 541-543
Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19.
N Engl J Med. 2020; 383: 120-128
SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis.
Am J Clin Pathol. 2020; 154: 466-474
Lung pathology of fatal severe acute respiratory syndrome.
Lancet. 2003; 361: 1773-1778
The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice.
Anaesthesia. 2020; 75: 724-732
COVID-19 pneumonia: different respiratory treatments for different phenotypes?.
Intensive Care Med. 2020; 46: 1099-1102
Caution about early intubation and mechanical ventilation in COVID-19.
Ann Intensive Care. 2020; 10: 78
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study.
Lancet Respir Med. 2020; 8: 1201-1208
The respiratory drive: an overlooked tile of COVID-19 pathophysiology.
Am J Respir Crit Care Med. 2020; 202: 1079-1080
Pulmonary fibrosis: pathogenesis, etiology and regulation.
Mucosal Immunol. 2009; 2: 103-121
Urgent avenues in the treatment of COVID-19: targeting downstream inflammation to prevent catastrophic syndrome.
Joint Bone Spine. 2020; 87: 191-193
A potential treatment of COVID-19 with TGF-β blockade.
Int J Biol Sci. 2020; 16: 1954-1955
Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?.
Eur Respir J. 2020; 562003167
Pathology and pathogenesis of severe acute respiratory syndrome.
Am J Pathol. 2007; 170: 1136-1147
Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors.
Thorax. 2005; 60: 401-409
Functional disability 5 years after acute respiratory distress syndrome.
N Engl J Med. 2011; 364: 1293-1304
Pulmonary pathology of severe acute respiratory syndrome in Toronto.
Mod Pathol. 2005; 18: 1-10
Pathogenetic mechanisms of severe acute respiratory syndrome.
Virus Res. 2008; 133: 4-12
Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.
Int J Legal Med. 2020; 134: 1275-1284
COVID-19 autopsies, Oklahoma, USA.
Am J Clin Pathol. 2020; 153: 725-733
CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients.
Eur Radiol. 2020; 30: 6129-6138
Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia.
Korean J Radiol. 2020; 21: 746-755
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
Thromb Res. 2020; 191: 145-147
Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.
J Vasc Surg Venous Lymphat Disord. 2021; 9: 23-35
Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients.
JAMA Surg. 2015; 150: 941-948
Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from ‘Spanish flu’ 1918/1919 in Switzerland to Coronavirus disease 2019.
J Pathol Clin Res. 2021; 7: 135-143
Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.
JAMA Intern Med. 2020; 180: 934-943
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020; 395: 1054-1062
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.
BMJ. 2020; 368m1091
Clinical characteristics of Covid-19 in New York City.
N Engl J Med. 2020; 382: 2372-2374
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.
J Thromb Haemost. 2020; 18: 1023-1026
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.
Lancet Respir Med. 2020; 8: 1233-1244
Laboratory abnormalities in patients with COVID-2019 infection.
Clin Chem Lab Med. 2020; 58: 1131-1134
Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study.
ESC Heart Fail. 2021; 8: 37-46
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.
J Clin Invest. 2020; 130: 4694-4703
Endothelial cell infection and endotheliitis in COVID-19.
Lancet. 2020; 395: 1417-1418
The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation.
Virchows Arch. 2020; 477: 349-357
In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19.
Mod Pathol. 2020; 33: 2104-2114
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.
Kidney Int. 2020; 98: 219-227
The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities.
Cardiovasc Pathol. 2020; 48107233
Diffuse alveolar damage and thrombotic microangiopathy are the main histopathological findings in lung tissue biopsy samples of COVID-19 patients.
Pathol Res Pract. 2020; 216153228
The unique characteristics of COVID-19 coagulopathy.
Crit Care. 2020; 24: 360
Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection.
Intensive Care Med. 2020; 46: 1124-1126
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.
Lancet Rheumatol. 2020; 2: e437-e445
Thrombolysis restores perfusion in COVID-19 hypoxia.
Br J Haematol. 2020; 190: e270-e274
Coagulopathy and antiphospholipid antibodies in patients with Covid-19.
N Engl J Med. 2020; 382: e38
Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
JAMA. 2020; 323: 1061-1069
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study.
Lancet Respir Med. 2021; 9: 139-148
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.
Lancet Respir Med. 2020; 8: 1209-1218
Multiorgan and renal tropism of SARS-CoV-2.
N Engl J Med. 2020; 383: 590-592
Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study.
Ann Intern Med. 2020; 173: 268-277
Transcriptional profiling of leukocytes in critically ill COVID19 patients: implications for interferon response and coagulation.
Intensive Care Med Exp. 2020; 8: 75
Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage.
Elife. 2021; 10e60361
COVID-19, ACE2, and the cardiovascular consequences.
Am J Physiol Heart Circ Physiol. 2020; 318: H1084-H1090
Mechanisms and treatment of organ failure in sepsis.
Nat Rev Nephrol. 2018; 14: 417-427
Extrapulmonary manifestations of COVID-19.
Nat Med. 2020; 26: 1017-1032
Toll-like receptors and COVID-19: a two-faced story with an exciting ending.
Future Sci OA. 2020; 6FSO605
Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection.
MBio. 2015; 6: e00638-e00715
Presence of genetic variants among young men with severe COVID-19.
JAMA. 2020; 324: 663-673
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Science. 2020; 370eabd4570
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.
Nat Rev Immunol. 2020; 20: 355-362
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020; 395: 497-506
Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19.
Crit Care. 2020; 24: 691
Is a “cytokine storm” relevant to COVID-19?.
JAMA Intern Med. 2020; 180: 1152-1154
Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019.
Clin Infect Dis. 2020; 71: 1937-1942
Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.
Cell Discov. 2020; 6: 31
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.
J Med Virol. 2020; 92: 791-796
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.
Intensive Care Med. 2020; 46: 846-848
Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality.
Am J Physiol Regul Integr Comp Physiol. 2021; 320: R250-R257
Clinical and immunologic features in severe and moderate coronavirus disease 2019.
J Clin Invest. 2020; 130: 2620-2629
Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.
Cell Discov. 2020; 6: 31
A longitudinal study of immune cells in severe COVID-19 patients.
Front Immunol. 2020; 11580250
Complex immune dysregulation in COVID-19 patients with severe respiratory failure.
Cell Host Microbe. 2020; 27: 992-1000.e3
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection.
Nat Med. 2020; 26: 1701-1707
Multisystem inflammatory syndrome in U.S. children and adolescents.
N Engl J Med. 2020; 383: 334-346
Multisystem inflammatory syndrome in children in New York State.
N Engl J Med. 2020; 383: 347-358
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Science. 2020; 370eabd4585
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
Science. 2020; 369: 718-724
Imbalanced host response to SARS-CoV-2 drives development of COVID-19.
Cell. 2020; 181: 1036-1045.e9
Type I IFN immunoprofiling in COVID-19 patients.
J Allergy Clin Immunol. 2020; 146: 206-208.e2
Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.
Nat Immunol. 2021; 22: 32-40
Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19.
Sci Immunol. 2020; 5eabd1554
Cytokine levels in critically ill patients with COVID-19 and other conditions.
JAMA. 2020; 324: 1565-1567
COVID-19: What type of cytokine storm are we dealing with?.
J Med Virol. 2021; 93: 197-198
Heightened innate immune responses in the respiratory tract of COVID-19 patients.
Cell Host Microbe. 2020; 27: 883-890.e2
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.
Emerg Microbes Infect. 2020; 9: 761-770
Compartmental immunophenotyping in COVID-19 ARDS: a case series.
J Allergy Clin Immunol. 2021; 147: 81-91
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Nature. 2020; 588: 146-150
A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids.
Cell Stem Cell. 2020; 27: 125-136.e7
Two distinct immunopathological profiles in autopsy lungs of COVID-19.
Nat Commun. 2020; 115086
Inflammasome formation in the lungs of patients with fatal COVID-19.
Inflamm Res. 2021; 70: 7-10
Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues.
Infect Dis Poverty. 2020; 9: 45
Hyperferritinemia in critically ill patients.
Crit Care Med. 2020; 48: 459-465
Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis.
BMC Med. 2017; 15: 172
Predictors of in-hospital COVID-19 mortality: a comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions.
PLoS One. 2020; 15e0241742
Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
J Clin Lab Anal. 2020; 34e23618
High mortality in COVID-19 patients with mild respiratory disease.
Eur J Clin Invest. 2020; 50e13314
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.
Blood. 2020; 136: 489-500
Anakinra for severe forms of COVID-19: a cohort study.
Lancet Rheumatol. 2020; 2: e393-e400
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
Lancet Rheumatol. 2020; 2: e325-e331
Favorable anakinra responses in severe covid-19 patients with secondary hemophagocytic lymphohistiocytosis.
Cell Host Microbe. 2020; 28: 117-123.e1
A review of the main histopathological findings in coronavirus disease 2019.
Hum Pathol. 2020; 105: 74-83
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.
Arthritis Rheumatol. 2014; 66: 2613-2620
Immune-inflammatory parameters in COVID-19 cases: a systematic review and meta-analysis.
Front Med (Lausanne). 2020; 7: 301
COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.
Crit Care. 2020; 24: 263
Complement activation in patients with COVID-19: a novel therapeutic target.
J Allergy Clin Immunol. 2020; 146: 215-217
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
Proc Natl Acad Sci USA. 2020; 117: 25018-25025
Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.
BMC Med. 2011; 9: 107
Review of clinical practice guidelines on the use of procalcitonin in infections.
Infect Dis (Lond). 2020; 52: 227-234
Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.
Clin Chim Acta. 2020; 509: 180-194
Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis.
Med Clin (Barc). 2020; 155: 143-151
Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times?.
Crit Care. 2020; 24: 600
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Lancet Respir Med. 2020; 8: 475-481
COVID-19 in people with diabetes: understanding the reasons for worse outcomes.
Lancet Diabetes Endocrinol. 2020; 8: 782-792
Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS.
Diabet Med. 2006; 23: 623-628
Expression profile of SARS-CoV-2 host receptors in human pancreatic islets revealed upregulation of ACE2 in diabetic donors.
Biology (Basel). 2020; 9: E215
COVID-19 and the endocrine system: exploring the unexplored.
J Endocrinol Invest. 2020; 43: 1027-1031
Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes.
Cell Metab. 2020; 31: 1068-1077.e3
Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a mendelian randomization analysis highlights tentative relevance of diabetes-related traits.
Diabetes Care. 2020; 43: 1416-1426
Glycemic variability in diabetes increases the severity of influenza.
MBio. 2020; 11: e02841-e02849
Diabetes exacerbates infection via hyperinflammation by signaling through TLR4 and RAGE.
MBio. 2017; 8: e00818-e00917
COVID-19, diabetes mellitus and ACE2: the conundrum.
Diabetes Res Clin Pract. 2020; 162108132
COVID-19 and the RAAS-a potential role for angiotensin II?.
Crit Care. 2020; 24: 136
Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality.
JAMA. 2020; 324: 168-177
Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors.
Circ Res. 1999; 84: 695-703
SARS-CoV-2 as a factor to disbalance the renin-angiotensin system: a suspect in the case of exacerbated IL-6 production.
J Immunol. 2020; 205: 1198-1206
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Eur J Intern Med. 2020; 76: 14-20
Impact of sex and gender on COVID-19 outcomes in Europe.
Biol Sex Differ. 2020; 11: 29
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Ann Oncol. 2020; 31: 1040-1045
Considering how biological sex impacts immune responses and COVID-19 outcomes.
Nat Rev Immunol. 2020; 20: 442-447
Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China.
Clin Infect Dis. 2020; 71: 762-768
Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients.
Crit Care. 2020; 24: 288
Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19.
Nat Commun. 2020; 115243
Comprehensive mapping of immune perturbations associated with severe COVID-19.
Sci Immunol. 2020; 5eabd7114
An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19.
Clin Infect Dis. 2020; 71: 2272-2275
Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19.
Cell. 2020; 182: 1401-1418.e18
Severe COVID-19 is marked by a dysregulated myeloid cell compartment.
Cell. 2020; 182: 1419-1440.e23
Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19).
Cell Death Differ. 2020; 27: 3196-3207
Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response.
Infect Immun. 2012; 80: 2026-2034
A single-cell atlas of the peripheral immune response in patients with severe COVID-19.
Nat Med. 2020; 26: 1070-1076
Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
J Leukoc Biol. 2020; 108: 17-41
Neutrophil extracellular traps in COVID-19.
JCI Insight. 2020; 5e138999
Targeting potential drivers of COVID-19: Neutrophil extracellular traps.
J Exp Med. 2020; 217e20200652
Immunophenotyping of circulating leukocytes reveal non-specific activation of innate and adaptive immune systems in multi-system inflammatory syndrome of childhood temporally associated with SARS-Cov-2 infection: descriptive cohort study.
Preprints. 2020; ()
A longitudinal study of immune cells in severe COVID-19 patients.
Front Immunol. 2020; 11580250
A dynamic COVID-19 immune signature includes associations with poor prognosis.
Nat Med. 2020; 26: 1623-1635
Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients.
Natl Sci Rev. 2020; 7: 998-1002
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.
Nat Med. 2020; 26: 842-844
COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes.
J Clin Invest. 2020; 130: 6290-6300
Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia.
Nature. 2021; 590: 635-641
Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes.
Crit Care. 2020; 24: 110
Post-operative immune suppression is mediated via reversible, Interleukin-10 dependent pathways in circulating monocytes following major abdominal surgery.
PLoS One. 2018; 13e0203795
Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma.
Crit Care. 2010; 14: R208
Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.
Intensive Care Med. 2006; 32: 1175-1183
Differential down-regulation of HLA-DR on monocyte subpopulations during systemic inflammation.
Crit Care. 2010; 14: R61
Influence of surgical intervention in the immune response of severely injured patients.
Intensive Care Med. 2004; 30: 96-102
Reduced monocytic human leukocyte antigen-DR expression indicates immunosuppression in critically ill COVID-19 patients.
Anesth Analg. 2020; 131: 993-999
Systemically comparing host immunity between survived and deceased COVID-19 patients.
Cell Mol Immunol. 2020; 17: 875-877
Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.
Intensive Care Med. 2020; 46: 1769-1771
Coronavirus disease 2019 as a particular sepsis: a 2-week follow-up of standard immunological parameters in critically ill patients.
Intensive Care Med. 2020; 46: 1764-1765
Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock.
Crit Care. 2018; 22: 213
Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock.
Am J Respir Crit Care Med. 2004; 169: 1144-1151
The CD8 T cell response to respiratory virus infections.
Front Immunol. 2018; 9: 678
Decreased T cell populations contribute to the increased severity of COVID-19.
Clin Chim Acta. 2020; 508: 110-114
As plain as the nose on your face: the case for a nasal (mucosal) route of vaccine administration for Covid-19 disease prevention.
Front Immunol. 2020; 11591897
Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.
J Allergy Clin Immunol. 2020; 146: 89-100
T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019.
J Infect Dis. 2020; 222: 198-202
Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China.
JAMA Netw Open. 2020; 3e2010895
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.
Nat Commun. 2020; 113434
Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia.
J Infect Dis. 2020; 221: 1762-1769
The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.
Cell Death Dis. 2020; 11: 429
Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
Clin Exp Immunol. 2020; 201: 76-84
IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19.
JCI Insight. 2020; 5e139024
Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.
Clin Immunol. 2020; 217108486
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
EBioMedicine. 2020; 55102763
The laboratory tests and host immunity of COVID-19 patients with different severity of illness.
JCI Insight. 2020; 5e137799
Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.
JCI Insight. 2020; 5e140329
SARS-CoV-2-reactive interferon-gamma-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019.
J Med Virol. 2021; 93: 375-382
Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.
Cell. 2020; 181: 1489-1501.e15
Postmortem examination of patients with COVID-19.
JAMA. 2020; 323: 2518-2520
SARS-CoV-2 viral load is associated with increased disease severity and mortality.
Nat Commun. 2020; 115493
Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.
Intensive Care Med. 2021; 47: 188-198
Influenza A virus infection induces hyperresponsiveness in human lung tissue-resident and peripheral blood NK cells.
Front Immunol. 2019; 101116
Emerging insights into natural killer cells in human peripheral tissues.
Nat Rev Immunol. 2016; 16: 310-320
COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential.
Clin Immunol. 2020; 218108516
Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69−CD56dim cells.
J Allergy Clin Immunol. 2017; 139: 1321-1330.e4
Natural killer cell immunotypes related to COVID-19 disease severity.
Sci Immunol. 2020; 5eabd6832
Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2.
Cell Host Microbe. 2020; 28 (): 516
Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures.
Front Immunol. 2020; 11605170
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Nature. 2020; 584: 437-442
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.
Proc Natl Acad Sci USA. 2007; 104: 12123-12128
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
J Virol. 2004; 78: 6938-6945
Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.
Cell. 2020; 182: 73-84.e16
Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Nature. 2020; 584: 115-119
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia.
J Allergy Clin Immunol. 2020; 146: 211-213.e4
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.
Pediatr Allergy Immunol. 2020; 31: 565-569
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain.
Mult Scler Relat Disord. 2020; 42102185
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.
Mult Scler Relat Disord. 2020; 41102135
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Blood. 2020; 135: 1912-1915
In defense of evidence-based medicine for the treatment of COVID-19 acute respiratory distress syndrome.
Ann Am Thorac Soc. 2020; 17: 787-789